CD5N Stock Overview
Engages in the advertising technology and services business primarily in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Inuvo, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.22 |
| 52 Week High | US$0.49 |
| 52 Week Low | US$0.17 |
| Beta | 1.15 |
| 11 Month Change | 0.91% |
| 3 Month Change | -8.11% |
| 1 Year Change | -23.26% |
| 33 Year Change | -61.23% |
| 5 Year Change | -0.45% |
| Change since IPO | -89.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| CD5N | DE Software | DE Market | |
|---|---|---|---|
| 7D | 16.1% | 2.1% | 0.8% |
| 1Y | -23.3% | 53.9% | 9.1% |
Return vs Industry: CD5N underperformed the German Software industry which returned 55.4% over the past year.
Return vs Market: CD5N underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| CD5N volatility | |
|---|---|
| CD5N Average Weekly Movement | 13.1% |
| Software Industry Average Movement | 5.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CD5N's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: CD5N's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 82 | Rich Howe | inuvo.com |
Inuvo, Inc. engages in the advertising technology and services business primarily in the United States. It sells information technology solutions to brands, agencies, and large consolidators of advertising demand (platforms). Its platforms optimize the purchase and placement of advertising in real time.
Inuvo, Inc. Fundamentals Summary
| CD5N fundamental statistics | |
|---|---|
| Market cap | €32.44m |
| Earnings (TTM) | -€7.91m |
| Revenue (TTM) | €74.74m |
0.5x
P/S Ratio-5.0x
P/E RatioIs CD5N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CD5N income statement (TTM) | |
|---|---|
| Revenue | US$78.45m |
| Cost of Revenue | US$10.24m |
| Gross Profit | US$68.20m |
| Other Expenses | US$76.51m |
| Earnings | -US$8.30m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.059 |
| Gross Margin | 86.94% |
| Net Profit Margin | -10.59% |
| Debt/Equity Ratio | 0% |
How did CD5N perform over the long term?
See historical performance and comparison